tbuckley/cabot-search huggingface dataset:
Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)
Authors: Kirsten Fischer, Stephan Stilgenbauer, Carmen D Schweighofer, Raymonde Busch, Jasmin Renschler, Michael Kiehl, Leopold Balleisen, Michael J Eckart, Anna- Maria Fink, Julia Kilp, Matthias Ritgen, Sebastian Böttcher, Michael Kneba, Hartmut Döhner, Barbara F Eichhorst, Michael Hallek, Clemens- Martin Wendtner
Journal: Blood (2008)
Genetic variation and haplotype structures of the gene encoding human thymidylate synthase, a pharmacogenetic marker in fluoropyrimidine-treated cancer patients
Authors: L. Pare, E. del Río, D. Páez López-Bravo, M. Baiget
Journal: Journal of Clinical Oncology (2008)

14518 Background: Thymidylate synthase (TS) activity is an important determinant of response to chemotherapy with fluoropyrimidine prodrugs and its expression is largely determined by polymorphic features in the 5’ UTR region of the TS gene that can modify the number of the functional USF protein binding sites. Methods: DNA was extracted from peripheral blood from 587 caucasian cancer patients. Genotyping was performed by PCR amplification of the repeat region followed by automated sequencing Results: See Table. Conclusions: We define the genotypes of the 5’UTR region of the TS gene in a large cohort of caucasian cancer patients and we determine the number of functional USF binding sites that can be used as a pharmacogenetic marker in patients treated with fluoropyrimidines. The recently described 2RCC allele was also found in 6 patients, in all cases in heterozygous form. We identify a novel allele containing a 4bp insertion (cgcc) in the inverted repeat sequence located 2bp prior to the ATG start codon. In bold: novel allele. # Functional USF binding sites Genotypes* Colorectal cancer N (%) Breast cancer N (%) 1 2RGC/2RCC 0(0.0) 1(0.6) 2RCC/3RGCC 3(0.7) 0(0.0) 2 2RGC/2RGC 75(17.8) 40(24.1) 3RGCC/3RGCC 44(10.6) 13(7.8) 2RGC/3RGCC 103(24.5) 45(27.1) 2RCC/3RGGC 2(0.5) 0(0.0) 2RGC/3RGCC+ins6pb 4(1.0) 1(0.6) 3RGCC/3RGCC+ins6bp 3(0.7) 2(1.2) 3 3RGGC/3RGCC 75(17.8) 25(15.1) 2RGC/3RGGC 73(17.3) 27(16.3) 2RGC+ins4bp/3RGGC 1(0.2) 0(0.0) 3RGGC/3RGCC+ins6bp 3(0.7) 0(0.0) 4 3RGGC/3RGGC 32(7.6) 12(7.2) 2RGG/3RGGC 1(0.2) 0(0.0) 2RGC/4RGGGC 1(0.2) 0(0.0) 3RGGC/4RGGCC 1(0.2) 0(0.0) Total N: 421 Total N: 166 * According to Lincz et al. Int. J. Cancer 2007; 120:1930–34. No significant financial relationships to disclose.
Integrative Genomic and Proteomic Analysis Of Low-Dose ionizing Irradiation Effects On Bone Marrow Stromal Microenvironment and On Survival Of Pre-Leukemic Cells
Authors: Yoko Tabe, Linhua Jin, Yasuhito Hatanaka, Hiromichi Matsushita, Saiko Kazuno, Tsutomu Fujimura, Takashi Ueno, Keisuke Sasai, Kazuhisa Iwabuchi, Michael Andreeff, Marina Konopleva, Takashi Miida
Journal: Blood (2013)
BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.
Authors: Samir Parekh, Jose Polo, Przemyslaw Juszczynski, Paola Lev, Stella Ranuncolo, Georgio Cattoretti, Rita Shaknovich, Margaret Shipp, Ari Melnick
Journal: Blood (2006)
Percentage of Smudge Cells on Blood Smear Predicts Prognosis in Chronic Lymphocytic Leukemia: A Multicenter Study.
Authors: Grzegorz S. Nowakowski, James D. Hoyer, Tait D. Shanafelt, Diane F. Jelinek, Laura Z. Rassenti, Thomas J. Kipps, Neil E. Kay
Journal: Blood (2007)
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cell in human breast cancer cells.
Authors: Jin Zhang, Yunhui Hu, Yang Zhou, Jingjing Liu, Sheng Zhang
Journal: Journal of Clinical Oncology (2015)

e13509 Background: The multidrug resistance (MDR) phenotype always accompanies activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which renders a survival signal to cytotoxic anti-cancer drugs and enhances cancer stem cell (CSC) characteristics. This study was to evaluate the effect of apoptosis promoting and CSC eliminating when NVP-BKM120 (BKM120), a selective inhibitor of PI3K, was treated individually or combined with other anti-cancer drugs in MDR breast cancer cell lines. Methods: After treatment of BKM120, cytotoxic activity was measured by MTT assay and drug resistant clones formation assay, Annexin V/PI staining, tests of caspase-3/7 and caspase 9 activities were used to evaluate cell apoptosis, p-Akt, total Akt, NF-κB p65 subunit were observed by western blot analysis and immunofluorescence staining. We investigated the effect on CSC population and characteristics through mammosphere formation assay, soft agar colony formation assay, ALDH1 and CD44+/CD24- detecting by flow cytometry. The activity of BKM120 individually and synergistically with doxorubicin on MDR breast cancer cells was also evaluated. Results: BKM120 showed significant cytotoxic activity on MDR breast cancer cells both in vitro and in vivo. When doxorubicin was combined with BKM120, strong synergistic anti-proliferative effect on chemo-resistant breast cancer cells was noted. BKM120 activity induced the blockage of PI3K signaling, decreased Akt phosphorylation and NF-κB expression which leading to concomitant caspase 3/7 and caspase 9 activation, as well as changes of several apoptosis related genes expression. Furthermore, BKM120 reduced CSC sub-population and sphere formation capacity in vitro of drug resistant cells. Conclusions: Our findings suggested that BKM120 effectively inhibits the PI3K/Akt signaling pathway, which resulted in apoptosis induction and CSC abolishing through PI3K/Akt/ NF-κB axis. Further, combination of doxorubicin and BKM120 induce synergistic cytotoxicity and partially overcome MDR phenotype in chemo-resistant breast cancer.
TCT-600 Short and Mid-Term Outcomes of Diabetic Patients Treated with Everolimus-Eluting Bioresorbable Scaffolds Versus Second-Generation Drug Eluting Stents: a Propensity Score-Matched Analysis of ABSORB EXTEND and SPIRIT Clinical Trials
Authors: Carlos M. Campos, Alexandre Abizaid, Adriano Caixeta, Antonio L. Bartorelli, Robert J. Whitbourn, Marco A. Perin
Journal: Journal of the American College of Cardiology (2015)
A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash.
Authors: Thomas Goehler, Marcus A. Woerns, Holger Frithjof Hebart, Michael Heike, Michael Neise, Jochen Rudi, Thomas Geer, Gerrit Dingeldein, Claudia Lang, Peter Ehscheidt, Thomas Flohr, Klaus Maria Josten, Meinolf Karthaus, Alexander H. Schmittel, Jan Wierecky, Peter Robert Galle, Carmen Dhensaw, Markus Hermann Moehler, Carl Christoph Schimanski
Journal: Journal of Clinical Oncology (2014)

e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% develop a rash ≥ grade 3. Skin prophylaxis with oral doxycycline and topic hydrocortisone reduced the occurrence of rash. Vitamin K1 independently activates the EGFR- tyrosine kinase. Recent reports showed activity of vitamin K1 ointments in the prevention of skin rash. The primary endpoint of the DERMATUX trial is the 1-year progression free survival (PFS) rate of patients receiving skin prophylaxis with oral doxycycline and topical vitamin K1 ointment as compared to historical controls. Methods: This is a phase IV, multicenter, non-randomized trial with an initial sample size of 165 patients from 20 centers in Germany. Patients must have a wt-KRAS and EGFR-positive first line CRC stage 4. Major exclusion criteria are mt-KRAS, no EGFR-expression and chronic skin disorders. Eligible patients receive irinotecan 180 mg/m² (day 1), folinic acid 400 mg/m² (day 1), 5-FU 400 mg/² (day 1) and 5-FU 1.400 mg/m² (day 1 and 2) in combination with cetuximab (initial dose 400 mg² on day 1 and 250 mg/m² at the following infusions). In parallel, patients receive vitamin K1 ointment (0.1%) once daily and oral doxycycline 100 mg b.i.d.. Upon occurrence of a grade 3 rash, patients also receive a topical corticoid ointment b.i.d. and dose-reduced cetuximab. Cetuximab is stopped and patients are referred to a dermatologist in case of grade 4 rash. Primary endpoint is 1-year PFS rate. Secondary endpoints are: rash ≥ grade 2 (CTCAE V3), time to occurrence of rash ≥ grade 2, occurrence of paronychia / skin fissures, rater, OS, PFS, rate of secondary resection of liver metastasis, and safety. Results: Study start was Q1 2011. 23 centers were initiated, but the trial was stopped prematurely in Q3 2013 due to slow recruitment. 55 patients were recruited and are followed up until Q3 2017. Conclusions: So far, no SUSARs occurred. Interim analyses were not planned. No further practical issues were identified during set-up and early conduct of the study. Clinical trial information: 2010-019885-10.
Prognostic Impact of Mutations in the Nucleophosmin (NPM1) and of the FMS-Related Tyrosine Kinase 3 (FLT3) Genes in Elderly Patients with Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy
Authors: Anne Etienne, Cecile Borel, Sarah Reutenauer, Sylviane Olschwang, Marie-Joelle Mozziconacci, Eric Delabesse, Cecile Demur, Thomas Prebet, Francoise Huguet, Aude Charbonnier, Christian Recher, Norbert Vey
Journal: Blood (2008)
GW27-e0800 Cardiac Dysregulation and Myocardial Injury in a 6-Hydroxydopamine-Induced Rat Model of Sympathetic Denervation and Prevention effect of Guizhi Decoction
Authors: Li Xiao, Ma Dufang, Jiang Yuehua, Yang Jinlong, Jiang Ping
Journal: Journal of the American College of Cardiology (2016)
Multiple Strategies Based on MEK, mTOR and BCL-2 Signal Transduction Inhibition in Acute Lymphoblastic Leukemia (ALL)
Authors: Maria Rosaria Ricciardi, Samantha Decandia, Sara Santinelli, Chiara Gregorj, Fabiana De Cave, Maria Cristina Scerpa, Paola Bergamo, Francesco Libotte, Cinzia De Benedictis, Antonella Vitale, Maria Teresa Petrucci, Marina Konopleva, Michael Andreeff, Michele Milella, Robert Foa, Agostino Tafuri
Journal: Blood (2008)
A Phase II study to evaluate the efficacy of erlotinib in advanced NSCLC patients who have wild-type EGFR and EGFR gene amplification.
Authors: Takashi Sone, Tomoyuki Araya, Yuichi Tambo, Kazuhiko Shibata, Shingo Nishikawa, Ryo Matsunuma, Toshiyuki Kita, Koji Kurokawa, Hiroki Shirasaki, Masaru Nishitsuji, Josuke Hara, Satoshi Nomura, Hayato Koba, Tamami Sakai, Hirokazu Touge, Yoshihisa Ishiura, Shunichi Tamori, Hideharu Kimura, Taro Yoneda, Kazuo Kasahara
Journal: Journal of Clinical Oncology (2015)

e19028 Background: Erlotinib is one of the standard therapies for previously treated patients (pts) of advanced non-small-cell lung cancer (NSCLC) without EGFR mutations. However, response rate of erlotinib in patients with wild-type EGFR is limited to about 10%, it is unclear which factor is predictive marker of erlotinib in pts without EGFR mutations. We conducted a multicenter phase II trial to evaluate the efficacy and toxicity of erlotinib in previously treated pts with advanced NSCLC with wild-type EGFR and EGFR gene amplification (GA). Primary endpoint is disease control rate (DCR); secondary endpoints are safety, response rate, progression-free survival (PFS), and overall survival (OS). Methods: Eligibility required histologically confirmed NSCLC, without active EGFR mutations, previously treated with one to three chemotherapy regimens, measurable lesions, ECOG PS 0-2, and adequate organ functions. Tissue collection was mandatory to assess EGFR GA. Enrolled pts were received erlotinib until disease progression or intolerable toxicity. Sample size was calculated to be 120 based on the assumption that pts with EGFR GA is superior to those without of EGFR GA in DCR (50%, 45%), with α = 0.05 (two-sided) and power = 0.80. Results: From February 2010 to December 2013, 78 pts were enrolled from 12 institutions and 1 pt withdrew consent. The accumulation of the cases did not reach a planned size, but was finished by the time limit. Grade 3/4 toxicities included skin rash (5%), acute lung injury (3%), appetite loss (3%), liver injury (3%) and diarrhea (1%). DCR of all pts was 31.2%(CR 0, PR 1, SD 23, PD 50, NE 3). Median PFS and OS for all pts treated with erlotinib were 1.2 months (M) and 6.2 M. EGFR GA was evaluable in 57 pts and 20 pts (35.0%) showed EGFR GA. There was no difference in DCR, PFS and OS between pts with EGFR GA and those without EGFR GA (25.0% v 40.5%, p = 0.47), (1.0 M v 1.6 M, log-rank p = 0.17), (6.1 M v 5.8 M, log-rank p = 0.47). Conclusions: The result failed to show the efficacy of erlotinib in NSCLC pts with wild-type EGFR and EGFR GA. Clinical trial information: UMIN000004207.
Preventing patupilone-induced diarrhea with high-dose corticosteroids.
Authors: S. S. Sridhar, S. J. Hotte, C. K. Kollmannsberger, S. D. Mukherjee, K. Capier, J. Barclay, L. Adams, D. Weber, K. N. Chi
Journal: Journal of Clinical Oncology (2010)

e13069 Background: Patupilone (EPO906, Epothilone B) is a cytotoxic agent that induces mitotic cell cycle arrest and apoptosis in human cancer cells by causing microtubule stabilization. The major dose-limiting toxicity (DLT) of patupilone in humans is diarrhea. Patupilone-induced diarrhea is characterized by increased inflammation, impaired cytokine release, and disturbed water secretion or absorption in the colon resulting in necrosis and apoptosis of crypt cells which may contribute to diarrhea. A rat animal model revealed that prednisone can markedly decrease patupilone-induced diarrhea. This study evaluated the effect of high-dose prednisone coadministration with patupilone in patients with castration-resistant prostate cancer (CRPC). Methods: In a phase II study of CRPC patients, having failed one prior taxane regimen, and treated with patupilone at 10 mg/m2 given every 3 weeks, 4 out of 6 patients experienced first-cycle grade 3-4 gastrointestinal (GI) adverse events (AE). In a subsequent 77 patients treated at 8 mg/m2 the grade 3-4 GI AE rate was 14.3%. In this phase I, 3+3 dose escalation extension study, CRPC patients failing one prior taxane regimen, were treated with patupilone at doses of 9 or 10 mg/m2IV once every 3 weeks, given concurrently with prednisone 25 mg BID for 8 days (day 1-8) followed by tapering doses until day 14. Results: Seven pts have been treated at the 9 mg/m2 dose level, thus far receiving a total of 26 cycles and an average 3 cycles/pt (range 1-8). Only 1 pt experienced grade 3 or higher diarrhea at this dose level. At the 10 mg/m2 dose level, 7 pts have been treated, thus far receiving a total of 7 cycles and an average of 1 cycle/pt (range 1-2) with no pts experiencing grade 3 or higher first cycle GI AE. Overall patients have tolerated the higher doses of patupilone and concomitant steroids well with only grade 1-2 related adverse events reported including diarrhea, sensory neuropathy, pain, constipation, flatulence, lymphopenia and dysgeusia. Expansion of this dose level is ongoing. Conclusions: High-dose prednisone appears to be effective in preventing patupilone-induced diarrhea and may facilitate treatment with patupilone at 10mg/m2 dosing. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Novartis
TCT-488 Comparison of clinical outcomes between a novel prolonged stent inflation protocol with conventional rapid/inflation/deflation method
Authors: Srikanth Vallurupalli, Srikanth Kasula, Naga Venkata Krishna Chand Pothineni, Shiv kumar Agarwal, Zubair Ahmed, Abdul Hakeem, Uretsky Barry
Journal: Journal of the American College of Cardiology (2015)
Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin
Authors: Dan Y. Gui, Lucas B. Sullivan, Alba Luengo, Aaron M. Hosios, Lauren N. Bush, Nadege Gitego, Shawn M. Davidson, Elizaveta Freinkman, Craig J. Thomas, Matthew G. Vander Heiden
Journal: Cell Metabolism (2016)
Analysis of PRAME Protein Expression in Normal Lymphoid Tissues and during B Ontogenesis.
Authors: Lorena L. de Figueiredo-Pontes, Fabio M. do Nascimento, Rodrigo S. de Abreu e Lima, Rodrigo Proto-Siqueira, Aglair B. Garcia, Daniel M. Matos, Ivan T. Gout, Valery V. Filonenko, Marco A. Zago, Roberto P. Falcao, Eduardo M. Rego
Journal: Blood (2005)
Bilateral groin pain in a young man
Authors: Raju Vaishya, Amit Kumar Agarwal, Vipul Vijay
Journal: BMJ (2016)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Bilateral groin pain in a young man Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Rivaroxaban - An Oral, Direct Factor Xa Inhibitor - for Thromboprophylaxis after Total Knee Arthoplasty: The RECORD3 Trial.
Authors: Michael R. Lassen, Alexander G.G. Turpie, Nadia Rosencher, Lars C. Borris, Walter Ageno, Jay R. Lieberman, Tiemo J. Bandel, Frank Misselwitz
Journal: Blood (2007)
EU governments face demands to cut coal emissions
Authors: Rory Watson
Journal: BMJ (2016)

An alliance of public health and environmental campaigners has increased pressure on EU governments to impose tighter restrictions on emissions from coal power stations. New limits, they said, would drastically reduce both the number of premature deaths caused by burning coal and the health related costs.1

The groups—the Health and Environment Alliance, Climate Action Network Europe, WWF European Policy Office, and Sandbag—have criticised the way …
TCT-435 Feasibility And Success of Radial-Access Robotic Percutaneous Coronary Intervention: Insights From The PRECISION Registry
Authors: Ryan D. Madder, Paul T. Campbell, Ronald Caputo, Vijaykumar Kasi, Ehtisham Mahmud, J. Jeffrey Marshall, Manish Parikh, Tom P. Stys, David H. Wohns, Giora Weisz
Journal: Journal of the American College of Cardiology (2015)
Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.
Authors: Kevin H.M. Kuo, Jeannie Callum, Joseph Brandwein, Michael Crump, John E. Curtis, Vikas Gupta, Jeffrey H. Lipton, Dominic Pantalony, Aaron Schimmer, Andre Schuh, Graham Sher, David M. Sutton, Karen W.L. Yee, Armand Keating, Mark D. Minden, Hans A. Messner
Journal: Blood (2006)
GW27-e0894 Combination of Blood pressure, left atrium size and serum total bilirubin level at admission predicts risk of 3-year's clinical outcomes in non-ischemic cardiomyopathy patients
Authors: Li Xiaofei, Sun Wei, Yao Yan, Lu Minjie, Hua Wei, Zhang Shu, Fan Xiaohan
Journal: Journal of the American College of Cardiology (2016)
Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy
Authors: Courtney B. Rubin, Rosalie Elenitsas, Laura Taylor, Simon F. Lacey, Irina Kulikovskaya, Minnal Gupta, Jan J. Melenhorst, Alison Loren, Noelle Frey, Carl H. June, David Porter, Misha Rosenbach
Journal: Journal of the American Academy of Dermatology (2016)
MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene
Authors: Laura Z. Rassenti, Emanuela M. Ghia, Lillian Werner, Donna Neuberg, Muller Fabbri, Stefano Volinia, George F. Widhopf, Carlo M. Croce, Thomas J. Kipps
Journal: Blood (2011)
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis
Authors: Shuang G Zhao, S Laura Chang, Daniel E Spratt, Nicholas Erho, Menggang Yu, Hussam Al-Deen Ashab, Mohammed Alshalalfa, Corey Speers, Scott A Tomlins, Elai Davicioni, Adam P Dicker, Peter R Carroll, Matthew R Cooperberg, Stephen J Freedland, R Jeffrey Karnes, Ashley E Ross, Edward M Schaeffer, Robert B Den, Paul L Nguyen, Felix Y Feng
Journal: The Lancet Oncology (2016)
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
Authors: Nidal E. Muvarak, Khadiza Chowdhury, Limin Xia, Carine Robert, Eun Yong Choi, Yi Cai, Marina Bellani, Ying Zou, Zeba N. Singh, Vu H. Duong, Tyler Rutherford, Pratik Nagaria, Søren M. Bentzen, Michael M. Seidman, Maria R. Baer, Rena G. Lapidus, Stephen B. Baylin, Feyruz V. Rassool
Journal: Cancer Cell (2016)
GW27-e1068 The Improved Cell-Autonomy Role of Bay60 2770 in Doxorubicin-Cardiotoxicity Mediated by Up-Regulated Mitochondrial Ferritin and Balancing p-P53ser15: An omen of a New Hypothesis of Innovative Antitumor Approach to Cancer Therapy with Doxorubicin
Authors: Xiao Xiao Zhao, Like Guan, Kyunghye Lee, Xian Wu Cheng, Weon Kim
Journal: Journal of the American College of Cardiology (2016)
Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy.
Authors: Anita Adams, Tamana Hafid, Kari Kolm, Jolanta Jeziorowska, Deborah C Marcellus, Graeme A M Fraser, Ronan Foley, Michael Trus, Ann Benger, C. Tom Kouroukis
Journal: Blood (2009)
Long-term survivors in glioblastoma patients homogeneously treated with the Stupp regimen, clinical characteristics and MGMT status: Initial results from the GLIOCAT study.
Authors: Estela Pineda, Maria Martinez, Francesc Alameda, Natalia Garcia, Eugenia Verger, Núria de la Iglesia, Carlos Mesia, Oscar Gallego, Anna Estival, Teresa Pujol, Miguel J. Gil Gil, Laura Oleaga, Jaume Capellades, Cristina Carrato, Teresa Ribalta, Sira Domenech, Rafel Fuentes, Jose Maria Velarde, Carmen Balana
Journal: Journal of Clinical Oncology (2016)

e13513 Background: Prognosis of GBM pts is still poor with a median survival of 15 months; however a small fraction survives more than 30 months, defined in our study as long term survivors (LTS-30) Methods: We performed a multicenter retrospective and prospective study of newly GBM pts treated homogeneously with the Stupp Regimen. In the present sub-study we analyze clinical characteristics and MGMT status in LTS-30 compared with pts surviving less than 30 months. Data from IDH1 mutation will be available for ASCO meeting. Results: From 2005 to 2014, 432 GBM pts homogeneously treated with the Stuup Regimen were included with a median progression free survival (PFS) of 8 months and a median overall survival of 15 months, of which 41 (9.5%) were long term survivors LTS-30, with a median PFS of 17 months and a median OS of 38 months. In this population median karnofsky index (KPS) was better (90% versus 80%) with less patients with KPS inferior to 80% (6% versus 41%; p=0.004), and median age was also younger (58 versus 62 years; p=0.014) with more pts ≤50 years (46% vs 25%). Methylated MGMT status was more frequent in LTS-30, 71% versus 46%, p=0.031, as described previously by the German Glioma Network. Complete Stupp Regimen treatment and bevacizumab (BVZ) use at recurrence were associated with LTS-30 (68% vs 30%, p<0.001; 41% vs 14%, p=0.012, respectively). On multivariate analyses, KPS ≥ 80%, MGMT methylation and BVZ treatment at recurrence were independent predictors of LTS-30. Conclusions: Identifying potential long term survivors in glioblastoma might be a meaning endpoint in order to establish the best therapeutic strategy. Independent prognostic factors of LTS-30 in GBM pts treated homogeneously with Stupp regimen are KPS ≥ 80%, MGMT methylation and BVZ at recurrence. Multivariate model for LTS-30 OR p age≥50y 0.81 0.70 Stupp regimen complete 1.95 0.20 KPS≥80% 5.21 0.034 BVZ at recurrence 3.29 0.019 Gross total resection 1.42 0.512 MGMT methylation 3.57 0.017